A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF

Journal of Cystic Fibrosis

Volumn 12, Issue 1, 2013, Pages 42-48

  Dalbøge, Christina Schjellerup ^a   Pressler, Tacjana ^a   Høiby, Niels ^a,b   Nielsen, Kim Gjerum ^a   Johansen, Helle Krogh ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Anti staphylococcus treatment; Cystic fibrosis; MRSA; MSSA; Treatment effectiveness

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CLARITHROMYCIN; CLINDAMYCIN; DICLOXACILLIN; FUSIDIC ACID; LINEZOLID; PROBENECID; RIFAMPICIN; TOBRAMYCIN;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; CHILD; COHORT ANALYSIS; CYSTIC FIBROSIS; ERADICATION THERAPY; FEMALE; HUMAN; INCIDENCE; INFANT; INFECTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; OUTCOME ASSESSMENT; PREVALENCE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; COHORT STUDIES; CYSTIC FIBROSIS; DENMARK; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFANT; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870753453     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.06.005     Document Type: Article

References (33)

1. Walters S.M.A. Epidemilogy of cystic fibrosis. Cystic fibrosis 2007, 21-45. Hodder Arnold, London. G.D. Hodson ME, A. Bush (Eds.).
2. Armstrong D.S., Hook S.M., Jamsen K.M., et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol Dec 2005, 40(6):500-510.
3. Douglas T.A., Brennan S., Gard S., et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J Feb 2009, 33(2):305-311.
4. Ranganathan S.C., Parsons F., Gangell C., Brennan S., Stick S.M., Sly P.D. Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis. Thorax May 2011, 66(5):408-413.
5. Ratjen F., Comes G., Paul K., Posselt H.G., Wagner TO, Harms K. Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol Jan 2001, 31(1):13-16.
6. Smyth A., Walters S. Prophylactic antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003, (3). (CD001912).
7. Schneider M., Muhlemann K., Droz S., Couzinet S., Casaulta C., Zimmerli S. Clinical characteristics associated with isolation of small-colony variants of Staphylococcus aureus and Pseudomonas aeruginosa from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol May 2008, 46(5):832-834.
8. Besier S., Smaczny C., von Mallinckrodt C., et al. Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J Clin Microbiol Jan 2007, 45(1):168-172.
9. Hoffman L.R., Deziel E., D'Argenio D.A., et al. Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A Dec 26 2006, 103(52):19890-19895.
10. Szaff M., Hoiby N. Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis. Acta Paediatr Scand Sep 1982, 71(5):821-826.
11. Høiby N., Pressler T. Emerging pathogens in cystic fibrosis. Cystic Fibrosis. European Respiratory Monograph 2006, 66-78. European Respiratory Society Journals Ltd. A.K. Webb, F. Ratjen (Eds.).
12. Høiby N., Frederiksen B. Microbiology of cystic fibrosis 2000, 83-107. Arnold, London. 2nd ed. M. Hodson, D. Geddes (Eds.).
13. Larsen A.R., Stegger M., Sorum M. Spa typing directly from a mecA, spa and pvl multiplex PCR assay-a cost-effective improvement for methicillin-resistant Staphylococcus aureus surveillance. Clin Microbiol Infect Jun 2008, 14(6):611-614.
14. Hallin M., Friedrich A.W., Struelens M.J. Spa typing for epidemiological surveillance of Staphylococcus aureus. Methods Mol Biol 2009, 551:189-202.
15. Lee T.W., Brownlee K.G., Conway S.P., Denton M., Littlewood J.M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros Mar 2003, 2(1):29-34.
16. Fuchs H.J., Borowitz D.S., Christiansen D.H., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med Sep 8 1994, 331(10):637-642.
17. Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med Jan 1999, 159(1):179-187.
18. Wang X., Dockery D.W., Wypij D., Fay M.E., Ferris B.G. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol Feb 1993, 15(2):75-88.
19. Cystic Fibrosis Foundation Patient Registry Annual Data Report, Bethesda, Maryland 2009, [© 2011 Cystic Fibrosis Foundation].
20. Dasenbrook E.C., Checkley W., Merlo C.A., Konstan M.W., Lechtzin N., Boyle M.P. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA Jun 16 2010, 303(23):2386-2392.
21. Vanderhelst E., De Meirleir L., Verbanck S., Pierard D., Vincken W., Malfroot A. Prevalence and impact on FEV(1) decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with cystic fibrosis a single-center, case control study of 165 patients. J Cyst Fibros Jan 2012, 11(1):2-7.
22. DANMAP Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark 2010, 1-156. http://www.danmap.org.
23. Annual Report On Staphylococcus Aureus Bacteraemia Cases in Denmark. Cases in Denmark 2008.
24. Hansen C.R., Pressler T., Hoiby N., Johansen H.K. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients. J Cyst Fibros Jan 2009, 8(1):58-62.
25. Tramper-Stranders G.A., Wolfs T.F., Fleer A., Kimpen J.L., van der Ent C.K. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J Jan 2007, 26(1):8-12.
26. Olesen Hanne, et al. ECFS patient registry report on 2007 data 2010.
27. UK CF Registry Annual Data Report 2009, [© Cystic Fibrosis Trust 2011].
28. Branger C., Gardye C., Lambert-Zechovsky N. Persistence of Staphylococcus aureus strains among cystic fibrosis patients over extended periods of time. J Med Microbiol Oct 1996, 45(4):294-301.
29. Kahl B.C., Duebbers A., Lubritz G., et al. Population dynamics of persistent Staphylococcus aureus isolated from the airways of cystic fibrosis patients during a 6-year prospective study. J Clin Microbiol Sep 2003, 41(9):4424-4427.
30. Frederiksen B., Koch C., Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol May 1997, 23(5):330-335.
31. Gangell C., Gard S., Douglas T., et al. Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. Clin Infect Dis Sep 2011, 53(5):425-432.
32. McPhail G.L., Acton J.D., Fenchel M.C., Amin R.S., Seid M. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic Pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr Dec 2008, 153(6):752-757.
33. Stone A., Saiman L. Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis. Curr Opin Pulm Med 2007; Nov, 13(6).